Worst Biotech Stocks To Watch – AFFY, CYTX, OPXA, MNOV

Affymax, Inc. (NASDAQ:AFFY) is expected to released its fourth quarter earning 2012 on Thursday this week. The company in less than two weeks mortified shareholders after it and along with its licensing partner Takeda Pharmaceuticals declared the voluntary recall of anemia drug Omontys. This would be conference call for Omontys is far more important to the company as it has no other agenda other then that to attract investors.

Let’s have a short overview of the financial highlights of the stock, Shares of Affymax, Inc. (NASDAQ:AFFY) decreased -6.53% to settle at $3.29 on March 8, 2013.

AFFY has 130 employees. Sales of AFFY were 83.25 billion with net income of -54.58 million.

AFFY stock surged during the trade to the maximum level at $3.87 and at the lowest level of $3.22 after opening price of $3.41. AFFY has earning per share of $-1.52 while it has 37.17 million shares outstanding with institutional ownership of 90%.

The price to sales ratio of AFFY in past twelve months was calculated as 1.47 and price to cash ratio remained 1.24. While retunes ratios are concerned, the AFFY return on equity ratio is recorded as -64.94% and decreased -49.07% return on investment while its return on asset remain -40.89%.

Opexa Therapeutics Inc. (NASDAQ:OPXA) President and Chief Executive Officer Neil K. Warma presented their developing Tcelna™, a novel T-cell therapy for multiple sclerosis (MS), in a 6th Annual European Life Science CEO Forum, at the Hilton Zurich Airport Hotel in Zurich, Switzerland.

Let’s have a short overview of the financial highlights of the stock, Shares of Opexa Therapeutics Inc. (NASDAQ:OPXA) decreased -5.26% to settle at $1.80 on March 8, 2013.

OPXA has 19 employees. Net income of OPXA was -8.77 million.

OPXA stock surged during the trade to the maximum level at $1.88 and at the lowest level of $1.76 after opening price of $1.88. OPXA has earning per share of $-1.52 while it has 5.76 million shares outstanding with institutional ownership of 7%.

The price to cash ratio of OPXA in past twelve months was calculated as 6.80. While retunes ratios are concerned, the OPXA return on equity ratio is recorded as -155.18% and decreased -151.07% return on investment while its return on asset remain -111.78%.

Stocks

Cytori Therapeutics Inc. (USA) (NASDAQ:CYTX) has provide an outlook for 2013, with declaring 2012 business and financial report. According to the report the company pulls off record total revenues of $14.5 million as compare to the same quarter in 2011 for the year and fourth quarter ended $7.3 million, compared to $2.8 million, for the same quarter in 2011.

Cytori Therapeutics Inc. (USA) (NASDAQ:CYTX) stock in last session held volume of 601.873 shares as compare to its average volume of 372,305 shares. The stock after opening at $2.78 hit high price of $2.84 and then closed at $2.78 by falling -5.12%.

Looking at the revenue measures, the company generated sales of 10.01 million in last twelve months with income of $-35.36 million. The Company showed a negative -353.13% in the net profit margin and its operating margin is calculated as -315.87%. Company’s annual sales growth for the past five years was 4.75%.

CYTX past twelve months price to sales ratio was 16.34 and price to cash ratio recorded as 9.28. As far as the returns are concern, CYTX return on equity recorded as -3223.52% while its return on asset stayed at -80.76%.

MediciNova, Inc. (NASDAQ:MNOV) is going to release its fourth earning reports 2012 at the end of this month. The company which itself developing its business, mainly target on the development and acquisition of small-molecule therapeutics for the treatment of serious diseases for the US.

MediciNova, Inc. (NASDAQ:MNOV) stock in last session held volume of 76,389 shares as compare to its average volume of 243,677 shares. The stock after opening at $3.38 hit high price of $3.43 and then closed at $3.20 by falling -6.71%.

Looking at the revenue measures, the company generated sales of 0.77 million in last twelve months with income of $-12.03 million. The Company showed a negative -1565.30% in the net profit margin and its operating margin is calculated as -1500.53%.

MNOV past twelve months price to sales ratio was 71.48 and price to cash ratio recorded as 9.59. As far as the returns are concern, MNOV return on equity recorded as -66.93% while its return on asset stayed at -52.15%.

Leave a Reply